SubsidieMeestersChronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Projectdetails
Introduction
About 25% of the adult population experiences chronic pain, which disrupts daily activities and severely affects the patient’s quality of life. In Europe, the socioeconomic burden of chronic pain runs into billions of euros annually and represents 3–10% of the GDP.
Current Treatment Limitations
The current mainstays of pain treatment are non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, but their prolonged use is frequently associated with life-threatening adverse events and physical dependence.
Need for New Strategies
There is therefore an urgent need for new pharmacological strategies with superior efficacy and safety than those of NSAIDs and opioids.
Project Overview
PAIN-CARE proposes to address chronic pain signaling using inhibitors targeting the Schwann cell proalgesic pathway. Previous research has shown the crucial role of Schwann cells in sustaining chronic pain.
Objectives
This project aims at developing Schwann cell selective drugs for chronic pain treatment, creating more clinically ready compounds based on bifunctional chimeric antagonists, with an inhibitory activity 100% higher than that of the combination of the two individual antagonists in mouse chronic pain models.
Expected Outcomes
The new Schwann Cell selective Analgesic Drugs (SCADs) will provide a dramatic change in the pain treatment paradigm, reducing treatment-related side effects and improving persistence.
Methodology
During this PoC, we aim to identify lead bifunctional chimeric molecules that preferentially antagonise two Schwann cell proteins.
Testing and Validation
We will carry out tests in vitro and in vivo to demonstrate the novel compounds’ feasibility and superior inhibition efficiency when compared to the currently used compounds.
Commercialisation Strategy
Furthermore, our aim is to translate the results to a pre-commercialisation phase through the definition of the innovation commercial feasibility and potential, which will then be validated in discussions with relevant market players.
Intellectual Property Strategy
A strong IPR strategy will be designed to ensure an advantageous position in the value chain of analgesics for pain treatment.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-11-2023 |
| Einddatum | 30-4-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCSpenvoerder
- UNIVERSITA DEGLI STUDI DI FIRENZE
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Oral oxytocin for abdominal painThis project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens. | ERC Proof of... | € 150.000 | 2023 | Details |
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAINPersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients. | ERC Consolid... | € 1.618.278 | 2023 | Details |
Descending control of painDescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Uncovering the cortical cellular basis of specificity and chronicity of painThis project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief. | ERC Advanced... | € 2.468.700 | 2025 | Details |
Disruptive Therapies for the long-term relief of Osteoarthritis PainThe Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life. | ERC Consolid... | € 1.998.885 | 2023 | Details |
Oral oxytocin for abdominal pain
This project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens.
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN
PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.
Descending control of pain
DescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies.
Uncovering the cortical cellular basis of specificity and chronicity of pain
This project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief.
Disruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic painSea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment. | EIC Accelerator | € 2.499.035 | 2024 | Details |
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing LossHB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models. | EIC Accelerator | € 2.325.312 | 2022 | Details |
Piezo-driven theramesh: A revolutionary multifaceted actuator to repair the injured spinal cordPiezo4Spine aims to create a groundbreaking 3D bioprinted mesh therapy for spinal cord injury that enhances neural repair through targeted mechanotransduction and gene therapy. | EIC Pathfinder | € 3.537.120 | 2023 | Details |
LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIESThe project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy. | EIC Pathfinder | € 2.999.840 | 2024 | Details |
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain
Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss
HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.
Piezo-driven theramesh: A revolutionary multifaceted actuator to repair the injured spinal cord
Piezo4Spine aims to create a groundbreaking 3D bioprinted mesh therapy for spinal cord injury that enhances neural repair through targeted mechanotransduction and gene therapy.
LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIES
The project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy.